期刊文献+

帕罗西汀合并奥氮平治疗强迫症的疗效与安全性 被引量:3

The Effect Observation of Paroxetine Combined with Olanzapine in Treatment of Obsessive-compulsive Disorder
下载PDF
导出
摘要 目的:观察帕罗西汀合并奥氮平治疗强迫症的临床效果和不良反应。方法:将80例强迫症患者随机分成两组,每组40例,研究组服用帕罗西汀和奥氮平,对照组单用帕罗西汀,疗程均为8周。采用汉密顿焦虑量表(HAMA)、耶鲁-布朗强迫症状量表(Y-BOCS)评定临床疗效,采用副反应量表(TESS)评定副反应。结果:研究组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗第8周时两组Y-BOCS、HAMA评分比较差异有统计学意义(P<0.05)。两组TESS评分在治疗第1、2、4、8周末差异均无统计学意义(P>0.05)。结论:帕罗西汀合并奥氮平治疗强迫症可以提高疗效,安全性较好,不会明显增加不良反应。 Objective:To evaluate the clinical efficiency of Paroxetine combined with Olanzapine in treating obsessive-compulsive disorder.Method:80 patients with obsessive-compulsive disorder were randomly divided into study group and control group,40 cases in each group. Paroxetine and Olanzapine were given to the study group,while only paroxetine was given to the control group,the treatment course were 8 weeks.Yale-Brown obsessive compulsive scale (Y-BOCS),Hamilton anxiety scale(HAMA) were used before treatment and after 8 weeks treatment to assess the efficacy,treatment emergent symptom scale (TESS) was used to assess the side effects.Result:The total effective rate of observation group was higher than that of control group,the difference was significant (P〈0.05),while after 8 weeks treatment,Y-BOCS,HAMA scores between the two groups had significant difference(P〈0.05).While after 1,2,4, 8 weeks treatment,TESS scores between the two groups had no significant difference(P〉0.05).Conclusion:Paroxetine combined with Olanzapine in treatment of obsessive-compulsive disorder can improve therapeutic efficacy,the security is better,not increase adverse reactions.
出处 《中国医学创新》 CAS 2015年第27期40-42,共3页 Medical Innovation of China
基金 江西省科技厅科技计划项目(20123BBG70207)
关键词 帕罗西汀 奥氮平 强迫症 Paroxetine Olanzapine Obsessive-compulsive disorder
  • 相关文献

参考文献10

二级参考文献31

  • 1王登峰.自我和谐量表的编制[J].中国临床心理学杂志,1994,2(1):19-22. 被引量:544
  • 2梁海翔,李翔,任丽娜.奎硫平与氯丙嗪辅助碳酸锂治疗躁狂发作疗效分析[J].临床精神医学杂志,2005,15(3):173-174. 被引量:15
  • 3刘俊丽,刘云波,冯正直,杨国愉,夏本立,钟铁军,汪涛,廖雅琴,秦爱粉,王江澜,张艳,汪凤.12486名军人SCL-90测试结果分析[J].中国健康心理学杂志,2005,13(6):423-427. 被引量:96
  • 4Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiat, 2006, 51 ( 8 Suppl 2) : 9 -91.
  • 5Geller DA. Obsessive - compulsive and spectrum disorders in children and adolescents. Psychiatr Clin N Am, 2006, 29 (2) :353 -370.
  • 6Grados MA, Riddle MA. Pharmacological treatment of childhood obsessive- compulsive disorder: from theory to practice. J Clin Child Psyehol, 2001,30( 1 ) : 110 - 113.
  • 7Denys D, Fineberg N, Carey PD, et al. Quetiapine addition in obsessive- compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiat, 2007,61 ( 3 ) ;412 -414.
  • 8Denys D, Klompmakers AA, Westenberg HG. Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacol,2004,176 ( 2 ) : 195 - 203.
  • 9Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol, 2007, 100( 1 ) :4 - 22.
  • 10Mc Dongle C J, Epperson CN, Pelton GH, et al. A double - blind, placebo controlled study of fisperidone addition in serotonin reuptake inhibitor refractory obsessive compulsive disorder. Arch Gen Psyehiat, 2000, 57(3) :794 -801.

共引文献54

同被引文献45

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部